Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

Press Release

Erytech Pharma S.A. : Monthly information related to total number of voting rights and shares composing the share capital - July 31, 2018

Erytech Pharma S.A.
Posted on: 06 Aug 18

Article 223-16 of general regulation of French Autorité des Marchés Financiers  Lyon - France

Listing markets:
Euronext Paris from Euronext (Market segment B -  ISIN Code: FR0011471135- Symbol: ERYP) &
Nasdaq Global Select Market in the United-States (Symbol : ERYP)
Website : www.erytech.com

Date Total of shares composing the share capital Total of brut (1) voting rights  

Total of net (2) voting rights

 
December 31, 201717 937 55919 545 44319 542 943
January 1, 2018 17 940 035 (3) 19 543 919 (3) 19 541 419
February 28, 201817 940 03519 546 21919 543 719
March 31, 201817 940 03519 546 22119 543 721
April 30, 201817 940 03519 554 22119 551 721
May 31, 201817 940 03519 543 99119 541 491
June 30, 201817 940 03519 525 99119 523 491
July 31, 201817 940 03519 525 99119 523 491

(1)  Gross voting rights number (or « theoretical » voting rights) is used as a basis for calculating the crossing of the threshold. In accordance with article 223-11 of general regulation of Autorité des Marchés Financiers, this number is calculated on the basis of all shares carrying the single and double voting rights, including shares without voting rights.
(2)  Without treasury shares
(3)  The number of shares and voting rights increased due to issuance of shares consequently to warrants exercises and or end of vesting periods of free shares which a Board of Director will take notice of in the future. Erytech Pharma S.A. - English


This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.

The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: Erytech Pharma S.A. via GlobeNewswire
HUG#2209219
GlobeNewswire
globenewswire.com

Last updated on: 07/08/2018

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.